Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032140 | 1.00 | ACHE (0.60) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL10267804 | 1.00 | ACHE (0.60) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL4498251 | 1.00 | ACHE (0.60) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL7226969 | 1.00 | ACHE (0.60) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL765298 | 1.00 | ACHE (0.60) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL4498246 | 1.00 | ACHE (0.60) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL5744577 | 0.92 | ACHE (0.51) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL1036718 | 0.87 | ALDH1A1 (0.62) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL28461967 | 0.87 | ALDH1A1 (0.62) | ACHEALDH1A1MAPTFUCA1SLC18A3 | |
| SCHEMBL736286 | 0.87 | ALDH1A1 (0.62) | ACHEALDH1A1MAPTFUCA1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-114901660-A | Substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3394061-B1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (US) | 2020-03-11 | — | — | EP | disclosed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | disclosed |
| WO-2001085728-A2 | ANTIBACTERIAL CHIRAL 8-(SUBSTITUTED PIPERIDINO)-BENZO [I, J] QUINOLIZINES, PROCESSES, COMPOSITIONS AND METHODS OF TREATMENT | WOCKHARDT LIMITED (IN) | 2001-11-15 | — | — | WO | disclosed |
| US-5789595-A | ANTICOAGULANTS | TERUMO KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
| CN-1167485-A | Tetrahydroisoquinoline derivative and medicinal preparation containing the same | TERUMO CORP (JP) | 1997-12-10 | — | — | CN | disclosed |
| EP-0790247-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND MEDICINAL PREPARATION CONTAINING THE SAME | TERUMO KABUSHIKI KAISHA (JP) | 1997-08-20 | — | — | EP | disclosed |
| US-5322852-A | Antitumor, antiprotozoa agents | CIBA-GEIGY CORP. (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0558443-A1 | O-Piperidyl-(3/4)-hydroxylamines and O-piperidyl-(3/4)-alkyl-hydroxylamines and their use as ornithine decarboxylase inhibitors | CIBA-GEIGY AG (CH) | 1993-09-01 | — | — | EP | disclosed |
| EP-0106276-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4639522-A | HYPOTENSIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1987-01-27 | — | — | US | disclosed |
| EP-0106276-A2 | 1,4-Dihydropyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | ACHE 4513/4885ALDH1A1 2649/4885MAPT 411/4885 |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | ACHE 4513/4885ALDH1A1 2649/4885MAPT 411/4885 |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | ACHE 2629/4885ALDH1A1 4765/4885MAPT 4812/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | ACHE 4855/4885ALDH1A1 3647/4885MAPT 4392/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | ACHE 2629/4885ALDH1A1 4765/4885MAPT 4812/4885 |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | ALPI, POLR1C, POLI | ACHE 2557/4885ALDH1A1 2656/4885MAPT 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.